Seegene Inc., a prominent leader in advanced PCR molecular diagnostics, and Springer Nature, the prestigious publisher of Nature, are delighted to unveil the launch of the Nature Awards MDx Impact Grants. This initiative represents an extension of their strategic partnership and aims to drive significant advancements in the field of syndromic PCR diagnostic assays.
A New Era of Diagnostic Innovation
The Nature Awards MDx Impact Grants program is a pioneering effort designed to foster innovation in the development of diagnostic assays. Leveraging Seegene’s cutting-edge multiplex PCR technology, the program invites researchers from across the globe to propose new diagnostic tests that address human infectious diseases. The call for proposals is now open, with the application deadline set for December 2, 2024.
This initiative builds on the remarkable success of the 2023 Open Innovation Program, which saw an impressive 281 applications from 47 countries. Out of these, 26 projects were selected for their potential impact. With the launch of this second phase, Seegene and Springer Nature are committed to broadening participation and enhancing the quality and scope of innovation in molecular diagnostics.
Program Details and Support
- Funding and Resources: Successful applicants will receive substantial support, including research funding of up to USD 600,000 per project. Additionally, Seegene will provide essential resources such as syndromic PCR assays, extraction assays, consumables, instruments, and relevant software to facilitate the clinical research projects.
- Application and Evaluation Process: The evaluation process will commence with an initial review in February 2025, followed by on-site evaluations and final deliberations. Award recipients will be revealed in August 2025. The Nature Awards will oversee the submission and evaluation process, while Seegene will handle the overall program planning and conduct on-site evaluations.
Statements from Key Figures
Dr. Jik Young Park, Vice President and Head of Seegene’s R&D Division, commented on the collaboration: “We are excited to embark on this new phase with Springer Nature. The launch of this new program is a testament to the strong global interest generated by last year’s initiative. We remain dedicated to advancing the development and commercialization of innovative syndromic PCR products, driven by the creativity and expertise of researchers worldwide.”
Marc Spenlé, Chief Operating Officer of Springer Nature, added: “The Nature Awards MDx Impact Grants are designed to empower scientists to propose innovative ideas for product development. We anticipate this will significantly expand the range of diagnostic innovations and ensure that the projects address critical clinical needs. Springer Nature will utilize its extensive network in the scientific community to encourage robust participation and support the success of this collaborative program.”
A Strategic Investment in Open Innovation
The Nature Awards MDx Impact Grants represent a major investment in open innovation, aimed at accelerating the commercialization of multiplex PCR technology. This program underscores Seegene and Springer Nature’s commitment to enhancing molecular diagnostics and addressing unmet clinical needs. By fostering a collaborative environment for researchers, the grants aim to contribute to the advancement of diagnostic solutions, ultimately benefiting public health and enhancing global disease management.
